José M. Ponseti

<i>Tacrolimus for Myasthenia Gravis</i>

José M. Ponseti, Josep Gámez, Jamal Azem et al. · Annals of the New York Academy of Sciences · 2008 · 84 citations

Life Sciences, Immunology, Pharmacotherapy +14

Influence of ectopic thymic tissue on clinical outcome following extended thymectomy in generalized seropositive nonthymomatous myasthenia gravis

José M. Ponseti, Josep Gámez, Ramón Vilallonga et al. · European Journal of Cardio-Thoracic Surgery · 2008 · 57 citations

Medicine, Pathology, Surgery +13

Benefits of FK506 (tacrolimus) for residual, cyclosporin- and prednisone-resistant myasthenia gravis: one-year follow-up of an open-label study

José M. Ponseti, Jamal Azem, José Manuel Fort et al. · Clinical Neurology and Neurosurgery · 2004 · 42 citations

Medicine, Immunology, Pharmacotherapy +7

A comparison of long-term post-thymectomy outcome of anti-AChR-positive, anti-AChR-negative and anti-MuSK-positive patients with non-thymomatous myasthenia gravis

José M. Ponseti, Norma Caritg, Josep Gámez et al. · Expert Opinion on Biological Therapy · 2008 · 36 citations

Life Sciences, Immunology, Surgery +6

Post-thymectomy combined treatment of prednisone and tacrolimus versus prednisone alone for consolidation of complete stable remission in patients with myasthenia gravis: a non-randomized, non-controlled study

José M. Ponseti, Josep Gámez, Jamal Azem et al. · Current Medical Research and Opinion · 2007 · 22 citations

Medicine, Immunology, Surgery +8